Moderna (NASDAQ:MRNA) stock was last seen up 3.9% to trade at $250.95 after reporting third-quarter earnings of $0.38 per share on $1.3 billion in revenue, versus Wall Street estimates of a loss of $1.25 per share on roughly $882 million in revenue. The company also raised its 2026 revenue growth outlook to 15%-25%, up from the prior expectation of up to 10%.
The shares this morning toppled yesterday's more than four-year high, with today's upbeat sentiment putting the vaccine maker on pace for a sixth win in nine sessions. The stock is up 904% year over year while the $240 level is stepping up as support.
Bears have been piling on more than usual. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Moderna stock's 10-day put/call volume ratio of 1.28 ranks in the 96th percentile of its annual range.
Plus, it's worth mentioning MRNA also tends to outperform options traders' volatility expectations. This is per its Schaeffer's Volatility Scorecard (SVS) of 83 out of 100.
